NCT05094219

Brief Summary

Objective: Estimate the cost of disease and falls among people with Parkinson's disease living in Hong Kong. Design: Prospective cost-utility analysis (base year 2021) with one baseline and two follow-up assessments at 6 months and 12 months Participants: Community-dwelling participants with Parkinson's disease of both genders of any age. Intervention: Nil Outcome measures: Self-reported questionnaires will be used to obtain information about the healthcare utility. In addition, the number of falls, the severity of Parkinson' disease assessed using the MDS-Unified Parkinson's Disease Rating Scale, level of disability using the Hoehn and Yahr scale, balance using the Mini Balance Evaluation Systems Test and Activities-specific Balance Confidence (ABC) scale, risk of falls using Falls Efficacy Scale International and quality of life using the Short-form Health survey (SF-36) will be assessed. Predictors of cost include fall frequency, balance status, disease severity, level of disability, quality of life, and duration of disease. Analysis: A multiple regression analysis will be conducted to determine which predictor (independent variable) influence the overall cost. The level of statistical significance (α) will be set at p\<0.05. A Tornado plot will be constructed for the individual items of both direct and indirect cost having the minimum and maximum range set at the 25th and 75th percentile. Two-way analysis of variance (ANOVA) will assess the differences in healthcare cost among frequent, in-frequent and non-fallers. Spearman's or Pearson correlation coefficient will assess correlations between quality of life and healthcare cost; disease severity and healthcare cost; falls frequency and healthcare cost. Benefits to healthcare and health Cost-estimation highlights information required to enhance the health care service for the target population. Through a similar study among patients with cerebellar ataxia, our team demonstrated specific challenges that need additional support from the policy-makers such as employment following disability, visits to specialists, home-care, and community participation for people with cerebellar ataxia in Hong Kong. This study will highlight the strength and weakness of the current healthcare system to people of Hong Kong with Parkinson's disease, this will inform the challenges for the healthcare requiring additional attention which in turn will have a beneficial impact on the future service.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2023

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 17, 2021

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 26, 2021

Completed
2 years until next milestone

Study Start

First participant enrolled

November 1, 2023

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2026

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Completed
Last Updated

March 15, 2024

Status Verified

November 1, 2023

Enrollment Period

2.2 years

First QC Date

October 17, 2021

Last Update Submit

March 13, 2024

Conditions

Keywords

FallsCostDisease burdenEconomic evaluation

Outcome Measures

Primary Outcomes (1)

  • Healthcare cost

    We will estimate both direct and indirect cost using the self-reported questionnaires available in both English and Chinese languages. The following criteria were used to choose the individual items under direct and indirect costs: relevance to Parkinson's disease, relevance to falls and consequences of falls, how quantifiable the items are, based on the commonly estimated items in similar economic, and to the extent to which the item reflects and impacts the quality of life of people with Parkinson's disease.

    Ongoing assessment from day 1 until 12 months

Secondary Outcomes (7)

  • Number of falls

    Day 1 (T1), 6 months (T2) and 12 months (T3)

  • MDS-UPDRS

    Day 1 (T1), 6 months (T2) and 12 months (T3)

  • Hoehn and Yahr scale

    Day 1 (T1), 6 months (T2) and 12 months (T3)

  • MiniBESTest

    Day 1 (T1), 6 months (T2) and 12 months (T3)

  • Falls Efficacy Scale International (FES-I)

    Day 1 (T1), 6 months (T2) and 12 months (T3)

  • +2 more secondary outcomes

Study Arms (1)

Observation group

Patients with a confirmed diagnosis of Parkinson's disease will be followed up for 12 months from the date of enrollment.

Other: No intervention will be offered

Interventions

No intervention will be offered

Observation group

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Community-dwelling participants with a confirmed diagnosis of Parkinson's disease of both genders of any age and who are residing in Hong Kong

You may qualify if:

  • community-dwelling participants with a confirmed diagnosis of Parkinson's disease
  • both genders
  • any age
  • who are residing in Hong Kong.

You may not qualify if:

  • are wheelchair-bound or bed-ridden,
  • have atypical Parkinson's syndrome and
  • other associated major illness such as stroke.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

The Hong Kong Polytechnic University

Hung Hom, Kowloon, 00, Hong Kong

RECRUITING

Prince of Wales Hospital

Shatin, Hong Kong

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • Stanley J Winser, PhD

    The Hong Kong Polytechnic Universit

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 17, 2021

First Posted

October 26, 2021

Study Start

November 1, 2023

Primary Completion

January 1, 2026

Study Completion

June 1, 2026

Last Updated

March 15, 2024

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

The personnel identification of the included participants will not be revealed. The study-related data will be expressed using a unique identification ID number. Personnel identifications such as names or photos will not be identified in public events such as conference presentations.

Locations